Weekly Research Analysts’ Ratings Updates for Prothena (PRTA)

Prothena (NASDAQ: PRTA) recently received a number of ratings updates from brokerages and research firms:

• 8/14/2024 – Prothena had its price target lowered by analysts at Oppenheimer Holdings Inc. from $66.00 to $62.00. They now have an “outperform” rating on the stock.
• 8/12/2024 – Prothena had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 8/12/2024 – Prothena was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/9/2024 – Prothena had its price target lowered by analysts at Royal Bank of Canada from $28.00 to $24.00. They now have a “sector perform” rating on the stock.
• 6/26/2024 – Prothena had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $28.00 price target on the stock.

Prothena Trading Down 1.1 %

Shares of PRTA stock traded down $0.21 during trading hours on Wednesday, reaching $19.77. The company’s stock had a trading volume of 264,798 shares, compared to its average volume of 629,953. The stock has a market capitalization of $1.06 billion, a P/E ratio of -6.08 and a beta of 0.21. Prothena Co. plc has a one year low of $18.69 and a one year high of $61.45. The firm’s fifty day simple moving average is $21.50 and its 200 day simple moving average is $23.50.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.01) by $2.23. Prothena had a negative return on equity of 9.00% and a negative net margin of 23.44%. The firm had revenue of $132.01 million for the quarter, compared to analyst estimates of $10.73 million. During the same period last year, the company earned ($1.03) EPS. The business’s quarterly revenue was up 3184.7% compared to the same quarter last year. As a group, equities research analysts forecast that Prothena Co. plc will post -4.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Prothena

Several hedge funds have recently made changes to their positions in PRTA. DCF Advisers LLC raised its stake in Prothena by 0.5% during the second quarter. DCF Advisers LLC now owns 107,500 shares of the biotechnology company’s stock valued at $2,219,000 after buying an additional 500 shares during the last quarter. Signaturefd LLC grew its holdings in Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 863 shares during the period. ProShare Advisors LLC grew its holdings in Prothena by 8.9% during the first quarter. ProShare Advisors LLC now owns 11,346 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 932 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Prothena by 265.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,122 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Prothena by 13.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock worth $211,000 after acquiring an additional 1,186 shares during the period. 97.08% of the stock is currently owned by institutional investors.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.